Bronchiectasis epidemiology and demographics

Jump to navigation Jump to search

Bronchiectasis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bronchiectasis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bronchiectasis epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bronchiectasis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bronchiectasis epidemiology and demographics

CDC on Bronchiectasis epidemiology and demographics

Bronchiectasis epidemiology and demographics in the news

Blogs on Bronchiectasis epidemiology and demographics

Directions to Hospitals Treating Bronchiectasis

Risk calculators and risk factors for Bronchiectasis epidemiology and demographics

Overview

Bronchiectasis affects extremes of age in certain indigenous populations. It is difficult to estimate the prevalence because it is often misdiagnosed.

Bronchiectasis Epidemiology and Demographics

  • There is no known association of bronchiectasis and a particular race.
  • Bronchiectasis predominantly affect extremes of age with a slight female preponderance.[1] The women that are infected with primary Mycobacterium avium complex MAC) tend to be slender, caucasian, and older than 60 years. It is given the name of Lady Windermere syndrome which is named after a character in a novel by Oscar Wilde.
  • Very high prevalence has been described in certain indigenous populations such as Alaskan natives with 10-20/1000 children affected.[1]
  • A recent US study demonstrated a marked increased prevalence in older populations varying from 4.2/100,000 adults aged 18–34 years to 271.8/100,000 older than 75 years.[1]
  • Substantial socioeconomic cost is associated with frequent use of primary and secondary healthcare resources.[1]
  • A US epidemiological study of bronchiectasis-associated hospitalizations from 1993 to 2006 demonstrated an average annual hospitalization rate of 16.5/100,000 population with a significant annual increase of 2.4% in men and 3.0% in women.[1]
  • Bronchiectasis often goes unrecognized or is misdiagnosed as asthma or chronic obstructive pulmonary disease (COPD), leading to an underestimated prevalence.[1]
  • Before antibiotics, the symptoms on bronchiectasis began in the patient's first decade of life. In developed countries, the age of onset has move to adulthood (except those with cysts fibrosis).

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 McDonnell MJ, Ward C, Lordan JL, Rutherford RM (2013). "Non-cystic fibrosis bronchiectasis". QJM. 106 (8): 709–15. doi:10.1093/qjmed/hct109. PMID 23728208.

Template:WH Template:WS